MYC and medulloblastoma: In conclusion, our study demonstrates that Axitinib, a highly specific clinically available inhibitor of angiogenesis, displays marked cytotoxic activity against paediatric medulloblastoma cell lines modelling most aggressive c‐myc‐amplified Non‐WNT/Non‐SHH and SHH‐TP53‐mutated tumours.